Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion

Eri Banno, Yosuke Togashi, Yoshihisa Kobayashi, Hidetoshi Hayashi, Tetsuya Mitsudomi, Kazuto Nishio

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Background: A recent pooled analysis of the LUX-LUNG3 and LUX-LUNG6 trials suggested that afatinib (an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)) is especially effective against non-small cell lung cancer (NSCLC) carrying an EGFR exon 19 deletion. Materials and Methods: Stable viral transfectant HEK293 cell lines carrying an exon 19 deletion (HEK293/19 del) or exon 21 L858R mutation (HEK293/ L858R)) were created and their drug sensitivities to AG1478 (a reversible EGFR-TKI) and afatinib were examined using an MTT assay. Western blot analyses were performed to estimate the phosphorylation of EGFR. Results: In the HEK293/19 del, the 50% inhibitory concentration (IC50) of afatinib was significantly lower than that in the HEK293/ L858R. In addition, afatinib inhibited the phosphorylation of EGFR to a greater degree in the HEK293/19 del than in the HEK293/L858R. Conclusion: Our experimental findings suggest that afatinib is especially effective against NSCLC carrying an EGFR exon 19 deletion.

Original languageEnglish
Pages (from-to)2005-2008
Number of pages4
JournalAnticancer research
Volume35
Issue number4
Publication statusPublished - Apr 1 2015
Externally publishedYes

Keywords

  • Afatinib
  • Epidermal growth factor receptor gene mutation
  • Exon 19 deletion
  • Exon 21 L858R
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion'. Together they form a unique fingerprint.

Cite this